Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Attovia Therapeutics
Private
Proprietary biparatopic nanobody platform
Company Info
Recent News
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer
Careers & Job Openings